Stock & Investment
Palantir’s share price is approximately $166, with a market cap of around $390 billion and a high valuation of 360-380x PER. Q3 2025 showed robust revenue growth (63% YoY), strong margins, and significant government contracts, notably a $10 billion U.S. Army deal. However, valuation risks, volatility, regulatory challenges, and competition pose threats.
As of November 2025, shares are priced around $300, with a market cap near $4 trillion and a year-to-date gain of 70%. Q3 earnings show significant growth in revenue and net income. Risks include valuation debates, regulatory concerns, and heavy capital investments. Future scenarios range from bullish to bearish based on AI integration and market competition.
KMW is a Korean telecom equipment company focused on RF components for 4G and 5G base stations. It experienced significant growth during the 5G rollout but faced declines due to global investment slowdowns. Looking ahead, KMW may benefit from enhanced 5G and 6G demands, though risks include competitive pressures and dependency on major clients.
The stock currently trades at KRW 692, reflecting a 50% decline over the year amid ongoing losses. Bitgwang Jeonja, a KOSDAQ-listed telecom equipment manufacturer, has seen a change in ownership and faces governance concerns due to significant accumulated losses. Future scenarios depend heavily on market conditions and governance stability.
The company, focused on school uniforms, sports goods, and workwear, currently faces challenges with a declining core revenue from uniforms despite growth in sports merchandising and workwear. Its recent rights offer poses risks of shareholder dilution, while its low PBR suggests undervaluation amid significant market volatility and strategic expansion efforts.
As of November 21, 2025, Ilshin Bio’s share price is KRW 1,852, up 15.5%, with a market cap of KRW 81.9 billion. Despite experiencing revenue declines, signs of recovery emerged in 2025, marked by increased profits and order backlog. Valuations appear reasonable with potential for growth dependent on demand in bio infrastructure and market themes.
ABL Bio’s share price is KRW 178,800 with a market cap of KRW 9.8 trillion, reflecting a substantial 500% annual return. Despite a significant Q3 revenue decline, future expectations hinge on recent partnerships with GSK and Lilly. The company’s high valuation and volatile stock pattern pose risks, urging cautious investment strategies.
Coca-Cola’s share price is approximately $71.1, reflecting a market capitalization of $306 billion. Recent Q3 results indicate net revenues of $12.5 billion, up 5% YoY. The company focuses on steady dividend growth and cash flow, although faces risks from inflation, competition, and regulatory challenges while expanding in emerging markets.
Naver’s current share price is KRW 257,000, with a market cap of KRW 39 trillion. Record-high Q3 2025 earnings are attributed to growth in advertising, commerce, fintech, and content. Analysts recommend a buy, though risks include competition and regulatory challenges. Long-term growth is expected at 7-10% with AI initiative impacts being uncertain.
The company, a machinery firm listed on KOSDAQ, has seen its volatile share price swing dramatically, driven by supply-demand and investor sentiment rather than fundamentals. It faces persistent losses and bad debt issues with subsidiaries, raising concerns over its financial stability and potential dilution from capital measures. Investors should treat it as a high-risk, short-term trading vehicle.
